Linzess vs Rezdiffra
A side-by-side look at two gastrointestinal medications advertised on TV. Informational only — not medical advice.
| US Linzess | US Rezdiffra | |
|---|---|---|
| Generic name | linaclotide | resmetirom |
| Drug class | Guanylate Cyclase-C Agonist | Thyroid Hormone Receptor-Beta Agonist |
| Treats | Irritable bowel syndrome with constipation, chronic constipation | Metabolic dysfunction-associated steatohepatitis (MASH) |
| Category | Gastrointestinal | Gastrointestinal |
| Manufacturer | AbbVie/Ironwood | Madrigal Pharmaceuticals |
| Year approved | 2012 | 2024 |
| FDA warning | Black box warning | Moderate warnings |
| Est. TV ad spend | $140M | — |
| Common side effects | Diarrhea, Abdominal pain, Gas, Bloating | Diarrhea, Nausea, Itching, Gallbladder problems |
Rezdiffra
Frequently asked questions
Is Linzess or Rezdiffra better?
Neither is universally "better." Linzess (linaclotide) and Rezdiffra (resmetirom) are both used for gastrointestinal, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Linzess and Rezdiffra?
Linzess is a Guanylate Cyclase-C Agonist made by AbbVie/Ironwood, while Rezdiffra is a Thyroid Hormone Receptor-Beta Agonist made by Madrigal Pharmaceuticals. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Linzess has the larger estimated TV advertising budget of the two.